StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
9
Publishing Date
2023 - 10 - 21
1
2023 - 10 - 09
1
2023 - 08 - 22
1
2023 - 08 - 04
1
2022 - 10 - 10
1
2022 - 09 - 21
1
2022 - 04 - 01
1
2021 - 06 - 11
1
2021 - 04 - 11
1
Sector
Health technology
9
Tags
Approved
1
Bioindiana
1
Cancer
5
Cell
1
China
1
Companion
1
Congress
1
Diagnostic
1
Drug
1
Fda
2
Fda approval
1
Fda-approvals
1
Food
1
Foundationone
1
Gastrointestinal
1
Lung
2
N/a
6
Plus
1
Positive
1
Research
2
Results
1
Retevmo
5
Symposium
1
Test
1
Therapy
1
Thyroid
3
Treatment
1
Tumors
1
Entities
Eli lilly and company
9
Incyte corporation
1
Sanofi
1
Symbols
INCY
1
LLY
9
SNY
1
SNYNF
1
Exchanges
Nasdaq
1
Nyse
9
Crawled Date
2023 - 10 - 21
1
2023 - 10 - 09
1
2023 - 08 - 22
1
2023 - 08 - 04
1
2022 - 10 - 10
1
2022 - 09 - 22
1
2022 - 04 - 01
1
2021 - 06 - 11
1
2021 - 04 - 11
1
Crawled Time
00:00
1
01:00
1
11:00
1
12:00
1
12:20
1
16:20
1
18:00
1
18:17
1
20:20
1
Source
www.biospace.com
3
www.fda.gov
1
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
selpercatinib
save search
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published:
2023-10-21
(Crawled : 16:20)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
Email alert
Add to watchlist
retevmo
lung
congress
symposium
cancer
cell
thyroid
results
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
Published:
2023-10-09
(Crawled : 18:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
32.83%
|
O:
-0.21%
H:
2.8%
C:
1.37%
foundationone
drug
diagnostic
food
tumors
companion
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Published:
2023-08-22
(Crawled : 12:20)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
37.03%
|
O:
0.3%
H:
1.19%
C:
0.75%
retevmo
approved
cancer
thyroid
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy
Published:
2023-08-04
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
66.3%
|
O:
-0.53%
H:
0.0%
C:
0.0%
retevmo
plus
therapy
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
Published:
2022-10-10
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
20.37%
|
O:
-0.1%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
129.83%
|
O:
-0.13%
H:
0.24%
C:
-0.72%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
17.7%
|
O:
-0.82%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-22.95%
|
O:
0.2%
H:
0.1%
C:
-1.43%
treatment
lung
thyroid
china
FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Published:
2022-09-21
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
153.23%
|
O:
1.46%
H:
3.93%
C:
3.35%
retevmo
fda
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
Published:
2022-04-01
(Crawled : 11:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
162.17%
|
O:
-0.08%
H:
2.44%
C:
2.28%
retevmo
cancer
FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Published:
2021-06-11
(Crawled : 18:17)
- fda.gov
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
Email alert
Add to watchlist
fda
fda approval
cancer
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
Published:
2021-04-11
(Crawled : 20:20)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
306.94%
|
O:
-0.57%
H:
0.28%
C:
-0.88%
test
positive
cancer
gastrointestinal
research
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.